GlobeNewsWire · MBRX · November 10, 2026

Preclinical Data Show Annamycin Makes Pancreatic Cancer Responsive to Checkpoint Inhibitors, Opening a Combination Path with Immunotherapies

Get the app for more

Explore stock news, insights and company research.